A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer

Carcinogenesis

Volumn 36, Issue 1, 2015, Pages 49-59

  Slattery, Martha L ^a   Wolff, Roger K ^a   Lundgreen, Abbie ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; CONVERGENCE OF HORMONES INFLAMMATION AND ENERGY RELATED FACTOR; CYTOKINE; DUAL SPECIFICITY PHOSPHATASE 2; HAMARTIN; INITIATION FACTOR 4E; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; SELENOPROTEIN; SMAD3 PROTEIN; STAT3 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; INTERFERON; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR MARKER;

ADAPTIVE RANK TRUNCATION PRODUCT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHIEF SIGNALING; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC RISK SCORE; GENOTYPE; HUMAN; JAK-STAT SIGNALING; MAJOR CLINICAL STUDY; MALE; RECTUM CANCER; SIGNALING PATHWAY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHENOTYPE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIGNAL TRANSDUCTION; UNITED STATES;

ADULT; AGED; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERFERONS; JANUS KINASE 1; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TELOMERE; TRANSFORMING GROWTH FACTOR BETA; UNITED STATES;

EID: 85003052707     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu213     Document Type: Article

References (51)

1. Slattery,M.L. et al. (2009) Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev. Res. (Phila)., 2, 922–930.
2. Carling,D. (2004) Ampk. Curr. Biol., 14, R220.
3. Hardie,D.G. (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 144, 5179–5183.
4. Carling,D. (2004) The AMP-activated protein kinase cascade–a unifying system for energy control. Trends Biochem. Sci., 29, 18–24.
5. Viollet,B. et al. (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans., 31, 216–219.
6. Watson,C.J. et al. (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine, 12, 1232–1235.
7. Waldner,M.J. et al. (2010) VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J. Exp. Med., 207, 2855–2868.
8. Nilsson,B.O. (2007) Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflamm. Res., 56, 269–273.
9. McKay,L.I. et al. (1999) Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev., 20, 435–459.
10. De Bosscher,K. et al. (2006) Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene, 25, 6868–6886.
11. Chadwick,C.C. et al. (2005) Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc. Natl Acad. Sci. USA., 102, 2543–2548.
12. Ray,P. et al. (1997) Repression of interleukin-6 gene expression by 17 betaestradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett., 409, 79–85.
13. Gordon,K.J. et al. (2008) Role of transforming growth factor-beta super-family signaling pathways in human disease. Biochim. Biophys. Acta., 1782, 197–228.
14. Ono,M. (2008) Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci., 99, 1501–1506.
15. Slattery,M.L. et al. (1997) Energy balance and colon cancer–beyond physical activity. Cancer Res., 57, 75–80.
16. Slattery,M.L. et al. (2003) Physical activity and colorectal cancer. Am. J. Epidemiol., 158, 214–224.
17. Yu,K. et al. (2009) Pathway analysis by adaptive combination of P-values. Genet. Epidemiol., 33, 700–709.
18. Samowitz,W.S. et al. (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology, 129, 837–845.
19. Slattery,M.L. et al. (2000) Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J. Natl. Cancer Inst., 92, 1831–1836.
20. Slattery,M.L. et al. (2009) A comparison of colon and rectal somatic DNA alterations. Dis. Colon Rectum, 52, 1304–1311.
21. Slattery,M.L. et al. (2011) Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-β-signaling pathway. Carcinogenesis, 32, 318–326.
22. Slattery,M.L. et al. (2011) Variation in the CYP19A1 gene and risk of colon and rectal cancer. Cancer Causes Control, 22, 955–963.
23. Slattery,M.L. et al. (2012) Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PLoS One, 7, e37312.
24. Slattery,M.L. et al. (2014) VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival. Mol. Carcinog., 53 (suppl. 1), E140–E150.
25. Slattery,M.L. et al. (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis, 31, 1604–1611.
26. Slattery,M.L. et al. (2012) Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int. J. Cancer, 130, 2974–2980.
27. Slattery,M.L. et al. (2011) Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis, 32, 1660–1667.
28. Slattery,M.L. et al. (2012) MAP kinase genes and colon and rectal cancer. Carcinogenesis, 33, 2398–2408.
29. Slattery,M.L. et al. (2012) Genetic variation in the transforming growth factor-β-signaling pathway, lifestyle factors, and risk of colon or rectal cancer. Dis. Colon Rectum, 55, 532–540.
30. Slattery,M.L. et al. (2013) Dietary influence on MAPK-signaling pathways and risk of colon and rectal cancer. Nutr. Cancer, 65, 729–738.
31. Slattery,M.L. et al. (2012) Oxidative balance and colon and rectal cancer: interaction of lifestyle factors and genes. Mutat. Res., 734, 30–40.
32. Slattery,M.L. et al. (2011) Tumor necrosis factor-related genes and colon and rectal cancer. Int. J. Mol. Epidemiol. Genet., 2, 328–338.
33. Bondurant,K.L. et al. (2013) Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int. J. Cancer, 132, 905–915.
34. Slattery,M.L. et al. (2013) JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog., 52, 155–166.
35. Slattery,M.L. et al. (2004) Associations between BMI, energy intake, energy expenditure, VDR genotype and colon and rectal cancers (United States). Cancer Causes Control, 15, 863–872.
36. Hong,S. et al. (2007) Smad7 sensitizes tumor necrosis factor induced apoptosis through the inhibition of antiapoptotic gene expression by suppressing activation of the nuclear factor-kappaB pathway. Cancer Res., 67, 9577–9583.
37. Halder,S.K. et al. (2005) Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp. Cell Res., 307, 231–246.
38. Piccirillo,S.G., et al. (2006) Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found. Symp. Proc., 5, 59–81.
39. Piccirillo,S.G. et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature, 444, 761–765.
40. Peters,U. et al. (2012) Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum. Genet., 131, 217–234.
41. Yang,G. et al. (2010) Smad4-mediated TGF-beta signaling in tumorigenesis. Int. J. Biol. Sci., 6, 1–8.
42. Haricharan,S. et al. (2014) STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol. Cell. Endocrinol., 382, 560–569.
43. Wei,L. et al. (2008) New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin. Cell Dev. Biol., 19, 394–400.
44. Kim,S.R. et al. (2009) Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem. Biophys. Res. Commun., 387, 342–347.
45. Zhang,L. et al. (2005) A new cellular signaling mechanism for angiotensin II activation of NF-kappaB: an IkappaB-independent, RSK-mediated phosphorylation of p65. Arterioscler. Thromb. Vasc. Biol., 25, 1148–1153.
46. Tesz,G.J. et al. (2007) Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J. Biol. Chem., 282, 19302–19312.
47. Murtaugh,M.A. et al. (2006) Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. Nutr. Cancer, 55, 35–43.
48. Peters,U. et al.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Project Team. (2004) Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol. Biomarkers Prev., 13, 546–552.
49. Slattery,M.L. et al. (2006) PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control, 17, 239–249.
50. Daniel,C. et al. (2007) The TGFbeta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. J. Cell. Biochem., 102, 1420–1431.
51. Ogino,S. et al. (2011) Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut, 60, 397–411.